FDA warned Healthy Living Clinic that its website misbrands compounded semaglutide by comparing it to Wegovy, Ozempic, and Rybelsus.
What happened
In August 2025, FDA reviewed the website https://healthyliving.clinic and found it offered compounded drug products, including semaglutide. FDA said the website claim “It is also available under brand names like Wegovy, Ozempic, and Rybelsus” falsely implies the compounded products are the same as FDA-approved drugs. FDA called the claim false or misleading and the products misbranded.
What FDA found
FDA says the website claim is false or misleading labeling for a drug, which misbrands it.
FDCA § 502(a) [21 U.S.C. § 352(a)]FDA says the same claim in advertising or promotion of a compounded drug is false or misleading, which misbrands it.
FDCA § 502(bb) [21 U.S.C. § 352(bb)]FDA says introducing or delivering these misbranded drugs into interstate commerce is prohibited.
FDCA § 301(a) [21 U.S.C. § 331(a)]FDA says receiving or delivering misbranded drugs in interstate commerce is also prohibited.
FDCA § 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells the company to take immediate action, including ceasing the misleading claim, and to send OCQC/CDER a written response within 15 working days of receipt. The response must describe steps taken, how recurrence will be prevented, and include related documents; if the company disagrees, it must give reasoning and support.
Who should pay attention
- telehealth companies selling compounded semaglutide
- compounding pharmacies and clinics marketing compounded GLP-1 drugs
- online drug sellers making brand-name comparisons
This is a summary. Read the original letter on fda.gov.